The government study provides the most complete picture yet of early-onset cancers, finding the largest increases in four ...

Q1 2025 Earnings Call Transcript May 2, 2025 Operator: Thank you for standing by. Hello and welcome to the Summit Therapeutics Q1 2025 Earnings Conference Call. I would now like to turn the call over ...

Singer Small Doctor has expressed concern over the decline of Fuji music, a popular Yoruba genre. He believes the genre is “dying” due to a lack of new, rising stars. Small Doctor, on X ...

The latest episode of 'The Last of Us' season 2, released on April 28 in India, explores the aftermath of Joel's shocking death. Ellie and the Jackson community grapple with the loss, as seen in ...

It has been approved by the China's NMPA for: 1) the treatment of adult patients with locally advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC), who have previously ...

In announcing (Chinese) ivonescimab’s Chinese approval in first-line PD-L1-positive non-small cell lung cancer on Friday, Akeso noted that the bispecific drug slashed the risk of death by 22.3% ...

The drug, ivonescimab, was approved for previously untreated patients with non-small cell lung cancer who had detectable ... a roughly 22% reduced risk of death, with a hazard ratio of 0.777.

The absence of these NAM immune cells leads to an exaggerated inflammatory response against the COVID-19 virus, cell death ... in 2020 that a small fraction (less than 5%) of lung macrophages ...

Wang and his collaborators developed cell lines derived from patients with small cell lung cancer. When BRDT was suppressed in lung cancer cells, it significantly slowed tumor progression and ...

In 2023, they expanded the partnership with the deployment of Tempus’ Next platform to support clinical decision-making for non-small cell lung cancer (NSCLC) patients, helping physicians determine ...

BioNTech stock rocketed Wednesday after rival Summit Therapeutics unveiled promising results for a novel approach to lung cancer treatment.Summit's Akeso-partnered drug, ivonescimab, works by blocking ...

A 79-year-old who died from a rare and aggressive form of cancer may have been exposed to asbestos when she spent time at a UK RAF base, an inquest has heard. A sitting of Dublin District Coroner ...